BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2019 7:22:50 AM | Browse: 1205 | Download: 2076
 |
Received |
|
2019-02-20 07:42 |
|
Peer-Review Started |
|
2019-02-20 09:19 |
|
First Decision by Editorial Office Director |
|
2019-03-05 21:38 |
|
Return for Revision |
|
2019-03-07 06:24 |
|
Revised |
|
2019-03-12 08:21 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-03-15 09:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-03-16 22:34 |
|
Articles in Press |
|
2019-03-16 22:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-03-29 03:11 |
|
Publish the Manuscript Online |
|
2019-03-31 07:22 |
| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Review |
| Article Title |
Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto and Tetsuya Nakatsura |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tetsuya Nakatsura, MD, PhD, Doctor, Doctor, Professor, Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan. tnakatsu@east.ncc.go.jp |
| Key Words |
Hepatocellular carcinoma; Cancer immunotherapy; Immune checkpoint inhibitor; Glypican-3; Cancer vaccine; Clinical trials; Cytotoxic T-lymphocytes |
| Core Tip |
Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease, with a poor prognosis. Recent developments and advances in cancer immunotherapy, particularly immune checkpoint inhibitor therapy, could lead to a major paradigm shift in standard HCC therapy. This review aims to provide an overview of novel immunotherapies, including antigen-based immunotherapies such as glypican-3-targeted immunotherapy, and immune checkpoint inhibitor therapy against HCC. It also discusses the future prospects of cancer immunotherapy against HCC. |
| Publish Date |
2019-03-31 07:22 |
| Citation |
Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World J Meta-Anal 2019; 7(3): 80-95
|
| URL |
https://www.wjgnet.com/2308-3840/full/v7/i3/80.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v7.i3.80 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
